Recent Research Analysts’ Ratings Updates for Corbus Pharmaceuticals (CRBP)

by · The Cerbat Gem

Corbus Pharmaceuticals (NASDAQ: CRBP) has recently received a number of price target changes and ratings updates:

  • 3/12/2025 – Corbus Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $51.00 price target on the stock.
  • 3/12/2025 – Corbus Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock, down previously from $75.00.
  • 3/11/2025 – Corbus Pharmaceuticals had its price target lowered by analysts at Jefferies Financial Group Inc. from $70.00 to $53.00. They now have a “buy” rating on the stock.
  • 3/6/2025 – Corbus Pharmaceuticals was upgraded by analysts at StockNews.com to a “sell” rating.
  • 2/28/2025 – Corbus Pharmaceuticals is now covered by analysts at William Blair. They set an “outperform” rating on the stock.
  • 2/18/2025 – Corbus Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
  • 2/10/2025 – Corbus Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock, down previously from $80.00.
  • 1/13/2025 – Corbus Pharmaceuticals was upgraded by analysts at StockNews.com to a “sell” rating.

Corbus Pharmaceuticals Stock Down 5.9 %

CRBP stock traded down $0.41 during midday trading on Thursday, hitting $6.51. The company’s stock had a trading volume of 62,410 shares, compared to its average volume of 240,337. The stock’s 50-day moving average price is $9.67 and its 200 day moving average price is $19.44. Corbus Pharmaceuticals Holdings, Inc. has a 1 year low of $6.38 and a 1 year high of $61.90. The stock has a market cap of $79.22 million, a price-to-earnings ratio of -1.39 and a beta of 2.63.

Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report) last announced its quarterly earnings data on Tuesday, March 11th. The biopharmaceutical company reported ($0.78) earnings per share for the quarter, beating the consensus estimate of ($1.02) by $0.24. As a group, equities analysts forecast that Corbus Pharmaceuticals Holdings, Inc. will post -4.23 earnings per share for the current fiscal year.

Institutional Trading of Corbus Pharmaceuticals

A number of institutional investors have recently modified their holdings of the business. Victory Capital Management Inc. increased its position in shares of Corbus Pharmaceuticals by 29.9% during the third quarter. Victory Capital Management Inc. now owns 24,760 shares of the biopharmaceutical company’s stock valued at $511,000 after buying an additional 5,700 shares during the period. HealthInvest Partners AB boosted its stake in Corbus Pharmaceuticals by 77.9% in the third quarter. HealthInvest Partners AB now owns 69,573 shares of the biopharmaceutical company’s stock worth $1,435,000 after buying an additional 30,473 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Corbus Pharmaceuticals by 224.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 93,643 shares of the biopharmaceutical company’s stock valued at $1,932,000 after purchasing an additional 64,800 shares during the period. The Manufacturers Life Insurance Company increased its position in Corbus Pharmaceuticals by 7.6% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 22,731 shares of the biopharmaceutical company’s stock valued at $469,000 after purchasing an additional 1,600 shares during the period. Finally, FMR LLC boosted its stake in shares of Corbus Pharmaceuticals by 33.0% during the 3rd quarter. FMR LLC now owns 10,028 shares of the biopharmaceutical company’s stock valued at $207,000 after purchasing an additional 2,486 shares in the last quarter. 64.64% of the stock is currently owned by hedge funds and other institutional investors.

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.

Further Reading